Efficacy of dolutegravir + lamivudine q.d. with food in people with TB / HIV using a rifampicin‐based regimen: A retrospective observational case series
HIV Medicine · 2024
DOI: 10.1111/hiv.13632 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift HIV Medicine, 2024. Verfasst von Yanyun Dou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Chest Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, China. Hauptthemen laut MEDLINE: Lamivudine, Oxazines, Heterocyclic Compounds, 3-Ring, Pyridones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Liuzhou Science and Technology Program.
Abstract (Originalsprache)
Objectives
Dolutegravir + lamivudine (DTG + 3TC) is a first‐line regimen for people with HIV. However, there are still concerns about its efficacy in people with tuberculosis (TB)/HIV due to the lack of available evidence and drug–drug interaction with rifampicin.
Methods
A single‐centre retrospective observational case series was conducted in Guangxi Zhuang Autonomous Region, China. We included all people with TB/HIV on combined use of once‐daily (q.d.) dosing DTG + 3TC and rifampicin (RIF)‐containing anti‐TB regimens between 2020 and 2022. HIV‐RNA, CD4 cell counts were collected and analysed.
Results
In all, 21 people with HIV (PWH) were included in this study. All the PWH were treatment‐naïve and told to take DTG + 3TC q.d. with food. The median age was 53 years, and 71.43% were male. A total of 71.43% PWH had baseline viral load (VL) > 100 000 copies/mL, and 33.33% had baseline VL greater than 500 000 copies/mL. Only one PWH had CD4 cell count greater than 200 cells/μL, and the median CD4 count was 20 cells/μL. A total of 16 PWH started DTG + 3TC after initiation of the RIF‐based anti‐TB regimen, and the other five PWH initiated DTG + 3TC before the treatment of TB. All the PWH had at least 24 weeks of follow‐up visits and all of the TB treatments were successful. A total of 20 PWH (95.24%) achieved viral suppression (VL
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chest Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, China.
ORCID-Profile: Yanyun Dou
Förderung
- Liuzhou Science and Technology Program
Zitieren
APA
Dou, Y., Lu, R., Su, L., Lan, K., Meng, Z., Qin, S., Huang, L., Huang, W., Xu, Y., Lv, Y., Wen, Y., Lan, S., Zuo, Y., & Zhang, Y. (2024). Efficacy of dolutegravir + lamivudine q.d. with food in people with TB / HIV using a rifampicin‐based regimen: A retrospective observational case series. HIV Medicine. https://doi.org/10.1111/hiv.13632
Vancouver
Dou Y, Lu R, Su L, Lan K, Meng Z, Qin S, et al. Efficacy of dolutegravir + lamivudine q.d. with food in people with TB / HIV using a rifampicin‐based regimen: A retrospective observational case series. HIV Medicine. 2024. doi:10.1111/hiv.13632
BibTeX
@article{Dou2024,
author = {Dou, Yanyun and Lu, Ruichao and Su, Lingsong and Lan, Ke and Meng, Zhihao and Qin, Shanfang and Huang, Liling and Huang, Wei and Xu, Yuanlong and Lv, Yu and Wen, Yuhong and Lan, Shuanglai and Zuo, Yong and Zhang, Yong},
title = {Efficacy of dolutegravir + lamivudine q.d. with food in people with TB / HIV using a rifampicin‐based regimen: A retrospective observational case series},
journal = {HIV Medicine},
year = {2024},
doi = {10.1111/hiv.13632}
}
EUVIMED